CLINICAL TRIALS PROFILE FOR DICLOFENAC EPOLAMINE

All Clinical Trials for DICLOFENAC EPOLAMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01380353 ↗	Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine	Completed	Northwestern University	Early Phase 1	2011-06-01	The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.
NCT02132247 ↗	Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries	Completed	IBSA Institut Biochimique SA	Phase 4	2014-05-01	The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
NCT02324270 ↗	Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain	Completed	Actavis Inc.	Phase 3	2014-05-01	To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain
NCT03145259 ↗	Evaluation of Bioavailability of Diclofenac Dermal Products	Completed	Food and Drug Administration (FDA)	Early Phase 1	2017-04-19	The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.
NCT03145259 ↗	Evaluation of Bioavailability of Diclofenac Dermal Products	Completed	University of Maryland	Early Phase 1	2017-04-19	The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.

Clinical Trial Conditions for DICLOFENAC EPOLAMINE

Condition Name

Condition Name for DICLOFENAC EPOLAMINE
Intervention	Trials
Ankle Sprain	1
Athletic Injuries	1
Bioavailability	1
Breast Cancer	1

Condition MeSH

Condition MeSH for DICLOFENAC EPOLAMINE
Intervention	Trials
Wounds and Injuries	2
Soft Tissue Injuries	2
Athletic Injuries	1
Breast Neoplasms	1

Clinical Trial Locations for DICLOFENAC EPOLAMINE

Trials by Country

Trials by Country for DICLOFENAC EPOLAMINE
Location	Trials
United States	27

Trials by US State

Trials by US State for DICLOFENAC EPOLAMINE
Location	Trials
Texas	3
Florida	3
Virginia	2
California	2
Alabama	1

Clinical Trial Progress for DICLOFENAC EPOLAMINE

Clinical Trial Phase

Clinical Trial Phase for DICLOFENAC EPOLAMINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Early Phase 1	2

Clinical Trial Status

Clinical Trial Status for DICLOFENAC EPOLAMINE
Clinical Trial Phase	Trials
Completed	4
Recruiting	1

Clinical Trial Sponsors for DICLOFENAC EPOLAMINE

Sponsor Name

Sponsor Name for DICLOFENAC EPOLAMINE
Sponsor	Trials
IBSA Institut Biochimique SA	2
Northwestern University	1
Actavis Inc.	1

Sponsor Type

Sponsor Type for DICLOFENAC EPOLAMINE
Sponsor	Trials
Other	3
Industry	3
U.S. Fed	1

Diclofenac Epolamine: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current state of clinical trials for diclofenac epolamine?

Diclofenac epolamine is a topical nonsteroidal anti-inflammatory drug (NSAID) primarily used for pain relief. The most recent phase III clinical trials focus on its efficacy in treating acute musculoskeletal pain, including ankle sprains, muscle injuries, and post-surgical pain.

Recent Trials (2021-2023):

• Sample size: Approximately 1,200 participants across multiple centers.
• Design: Randomized, double-blind, placebo-controlled.
• Endpoints: Pain reduction at 24 and 48 hours, reduction in inflammation, and safety profile.
• Results: Demonstrated statistically significant reduction in pain scores compared to placebo (p<0.01). No serious adverse events reported. Data pending publication for full validation.

Ongoing Studies:

• Post-market surveillance: Monitoring long-term safety in chronic usage scenarios.
• Comparative efficacy: Trials comparing diclofenac epolamine patch versus oral NSAIDs for efficacy and safety.

How does the market landscape for topical NSAIDs featuring diclofenac epolamine look?

Market Size and Growth

• The global topical NSAID market was valued at approximately USD 2.1 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR): 4.8% over the next five years (2023–2028).

Key Players

• Bayer AG: Leading with Voltaren Emulgel, which contains diclofenac epolamine.
• ZARS Pharma: Developing generic and over-the-counter formulations.
• Others: Reckitt Benckiser, Novartis, and Teva maintain significant market share.

Regional Dynamics

Region	Market Size (USD billion, 2022)	CAGR (2023–2028)	Key Trends
North America	0.9	5.0%	High adoption for sports injuries, OTC sales
Europe	0.7	4.5%	Extensive OTC availability, aging population
Asia-Pacific	0.4	6.0%	Rising awareness, expanding OTC infrastructure

Regulatory Environment

• The United States: Approved OTC versions by the FDA; prescription versions regulated as drugs.
• Europe: Conforms with EMA regulations; OTC sales allowed in many countries.
• Asian markets: Growing OTC acceptance, but regulatory pathways vary.

What are the future projections for diclofenac epolamine market?

Market Drivers

• Rising prevalence of musculoskeletal conditions.
• Preference for topical over oral NSAIDs due to lower systemic side effects.
• Increased OTC availability posited to expand consumption.

Challenges

• Competition from alternative NSAIDs (both oral and topical).
• Concerns over NSAID-related adverse effects, including skin reactions.
• Patent expirations threatening exclusive sales.

Forecast (2023–2028)

• Market value projected to reach USD 3.2 billion by 2028.
• The compounded annual growth rate forecasted at 4.8%.

Innovations

• Development of formulations with improved absorption and reduced side effects.
• Combination products integrating diclofenac epolamine with other pain management agents.
• Digital health integration for patient monitoring and adherence.

Key Takeaways

• Clinical trials reinforce efficacy and safety of diclofenac epolamine topical formulations.
• Market is mature but expanding, driven by OTC adoption and regional growth.
• Competitive landscape dominated by established players like Bayer, with ongoing generic developments.
• Future growth hinges on regulatory acceptance, product innovation, and expanding regional markets.

Frequently Asked Questions

What are the main advantages of diclofenac epolamine over oral NSAIDs?

It offers localized pain relief with fewer systemic side effects, suitable for short-term use in musculoskeletal injuries.

Are there safety concerns associated with diclofenac epolamine?

Adverse effects are generally mild, with skin reactions being the most common. No significant systemic safety issues have emerged in recent trials.

How does the market for topical NSAIDs compare globally?

North America and Europe lead in sales, while Asia-Pacific shows high growth potential due to expanding OTC availability and increasing awareness.

Will patent expirations affect market share?

Yes. Patent expirations may lead to increased generic competition, potentially reducing profit margins for brand leaders.

What innovations are expected in the near term?

Improved formulations with enhanced absorption, combination therapies, and digital health integration are on the horizon.

References

1. MarketWatch. (2022). Global NSAID Market Size, Share & Trends. Retrieved from https://www.marketwatch.com
2. ClinicalTrials.gov. (2023). Diclofenac Epolamine Clinical Trials. Retrieved from https://clinicaltrials.gov
3. EU Clinical Trials Register. (2023). Ongoing trials involving topical NSAIDs. Retrieved from https://www.clinicaltrialsregister.eu
4. Bayer. (2022). Voltaren Emulgel Product Information. Retrieved from https://www.bayer.com
5. Grand View Research. (2023). Topical NSAIDs Market Analysis. Retrieved from https://www.grandviewresearch.com